Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

Lack of association between interleukin-4 −524C>T polymorphism and colorectal cancer susceptibility

verfasst von: Huanlei Wu, Jia Hu, Bo Liu, Yu Tao, Xiao Zhou, Xianglin Yuan

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Interleukin-4 (IL-4) −524C > T polymorphism has been implicated to alter the risk of colorectal cancer (CRC), but the results are controversial. The objective of this study was to quantitatively evaluate the association between IL-4 −524C > T polymorphism and CRC risk. A comprehensive search was conducted to identify all eligible studies of IL-4 −524C > T polymorphism and CRC risk. Statistical analysis was performed with Review Manager 5.0 and Stata 11. A total of 5 case–control studies, including 1,224 cases and 1,551 controls, were included. The combined results based on all eligible studies suggested that IL-4 −524C > T polymorphism was not associated with CRC susceptibility. When stratifying for race, the data showed that the IL-4 −524C > T polymorphism was also not associated with an increased CRC susceptibility in Caucasians. Our study suggests that IL-4 −524C > T polymorphism may be not associated with an increased CRC susceptibility.
Literatur
1.
2.
Zurück zum Zitat Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–81.PubMedCrossRef Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–81.PubMedCrossRef
3.
Zurück zum Zitat Sung JJ, Lau JY, Goh KL, Leung WK. Asia Pacific Working Group on Colorectal Cancer. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005;6:871–6.PubMedCrossRef Sung JJ, Lau JY, Goh KL, Leung WK. Asia Pacific Working Group on Colorectal Cancer. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005;6:871–6.PubMedCrossRef
4.
5.
Zurück zum Zitat Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85.PubMedCrossRef Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85.PubMedCrossRef
6.
Zurück zum Zitat Sameer AS. Colorectal cancer: a researcher’s perspective of the molecular angel’s gone eccentric in the Vale of Kashmir. Tumor Biol. 2013;34:1301–15.CrossRef Sameer AS. Colorectal cancer: a researcher’s perspective of the molecular angel’s gone eccentric in the Vale of Kashmir. Tumor Biol. 2013;34:1301–15.CrossRef
7.
Zurück zum Zitat Baniyash M. Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin Cancer Biol. 2006;16:80–8.PubMedCrossRef Baniyash M. Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin Cancer Biol. 2006;16:80–8.PubMedCrossRef
8.
Zurück zum Zitat Zhang H, Xu Y, Zhang Z, Liu R, Ma B. Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol. 2012;13:14.PubMedCentralPubMedCrossRef Zhang H, Xu Y, Zhang Z, Liu R, Ma B. Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol. 2012;13:14.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Noguchi E, Nukaga-Nishio Y, Jian Z, Yokouchi Y, Kamioka M, et al. Haplotypes of the 5’ region of the IL-4 gene and SNPs in the intergene sequence between the IL-4 and IL-13 genes are associated with atopic asthma. Hum Immunol. 2001;62:1251–7.PubMedCrossRef Noguchi E, Nukaga-Nishio Y, Jian Z, Yokouchi Y, Kamioka M, et al. Haplotypes of the 5’ region of the IL-4 gene and SNPs in the intergene sequence between the IL-4 and IL-13 genes are associated with atopic asthma. Hum Immunol. 2001;62:1251–7.PubMedCrossRef
11.
Zurück zum Zitat Yannopoulos A, Nikiteas N, Chatzitheofylaktou A, Tsigris C. The (−590 C/T) polymorphism in the interleukin-4 gene is associated with increased risk for early stages of corolectal adenocarcinoma. In Vivo. 2007;21:1031–5.PubMed Yannopoulos A, Nikiteas N, Chatzitheofylaktou A, Tsigris C. The (−590 C/T) polymorphism in the interleukin-4 gene is associated with increased risk for early stages of corolectal adenocarcinoma. In Vivo. 2007;21:1031–5.PubMed
12.
Zurück zum Zitat Cozar JM, Romero JM, Aptsiauri N, Vazquez F, Vilchez JR, Tallada M, et al. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol. 2007;68:698–704.PubMedCrossRef Cozar JM, Romero JM, Aptsiauri N, Vazquez F, Vilchez JR, Tallada M, et al. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol. 2007;68:698–704.PubMedCrossRef
13.
Zurück zum Zitat Wilkening S, Tavelin B, Canzian F, Enquist K, Palmqvist R, Altieri A, et al. Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis. 2008;29:1202–6.PubMedCrossRef Wilkening S, Tavelin B, Canzian F, Enquist K, Palmqvist R, Altieri A, et al. Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis. 2008;29:1202–6.PubMedCrossRef
14.
Zurück zum Zitat Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N. Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2006;15:1126–31.PubMedCrossRef Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N. Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2006;15:1126–31.PubMedCrossRef
15.
Zurück zum Zitat Suchy J, Kłujszo-Grabowska E, Kładny J, Cybulski C, Wokołorczyk D. Find all citations by this author (default).Or filter your current search Szymańska-Pasternak J, et al. Inflammatory response gene polymorphisms and their relationship with colorectal cancer risk. BMC Cancer. 2008;8:112.PubMedCentralPubMedCrossRef Suchy J, Kłujszo-Grabowska E, Kładny J, Cybulski C, Wokołorczyk D. Find all citations by this author (default).Or filter your current search Szymańska-Pasternak J, et al. Inflammatory response gene polymorphisms and their relationship with colorectal cancer risk. BMC Cancer. 2008;8:112.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Landi S, Bottari F, Gemignani F, Gioia-Patricola L, Guino E, Osorio A, et al. Interleukin-4 and interleukin-4 receptor polymorphisms and colorectal cancer risk. Eur J Cancer. 2007;43:762–8.PubMedCrossRef Landi S, Bottari F, Gemignani F, Gioia-Patricola L, Guino E, Osorio A, et al. Interleukin-4 and interleukin-4 receptor polymorphisms and colorectal cancer risk. Eur J Cancer. 2007;43:762–8.PubMedCrossRef
17.
18.
Zurück zum Zitat Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;273:1516–7.PubMedCrossRef Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;273:1516–7.PubMedCrossRef
19.
Zurück zum Zitat Zhang H, Xu Y, Zhang Z, Li L. The hOGG1 Ser326Cys polymorphism and prostate cancer risk: a meta-analysis of 2584 cases and 3234 controls. BMC Cancer. 2011;11:391.PubMedCentralPubMedCrossRef Zhang H, Xu Y, Zhang Z, Li L. The hOGG1 Ser326Cys polymorphism and prostate cancer risk: a meta-analysis of 2584 cases and 3234 controls. BMC Cancer. 2011;11:391.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Zhang H, Xu Y, Li L, Liu R, Ma B. The interleukin-6–174G/C polymorphism and prostate cancer risk: a systematic review and meta-analysis. Urol Int. 2012;88:447–53.PubMedCrossRef Zhang H, Xu Y, Li L, Liu R, Ma B. The interleukin-6–174G/C polymorphism and prostate cancer risk: a systematic review and meta-analysis. Urol Int. 2012;88:447–53.PubMedCrossRef
22.
Zurück zum Zitat Zhang H, Wang A, Ma H, Xu Y. Association between insulin receptor substrate 1 Gly972Arg polymorphism and cancer risk. Tumor Biol. 2013;34(5):2929–36.CrossRef Zhang H, Wang A, Ma H, Xu Y. Association between insulin receptor substrate 1 Gly972Arg polymorphism and cancer risk. Tumor Biol. 2013;34(5):2929–36.CrossRef
24.
Zurück zum Zitat Ito H, Inoue H, Ikeda H, Onimaru M, Yoshida A, Hosoya T, et al. Clinicopathological characteristics and treatment strategies in early gastric cancer: a retrospective cohort study. J Exp Clin Cancer Res. 2011;30:117.PubMedCentralPubMedCrossRef Ito H, Inoue H, Ikeda H, Onimaru M, Yoshida A, Hosoya T, et al. Clinicopathological characteristics and treatment strategies in early gastric cancer: a retrospective cohort study. J Exp Clin Cancer Res. 2011;30:117.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Zeng FR, Ling Y, Yang J, Tian XC, Yang X, Luo RC. X-ray repair cross-complementing group 1 Arg399Gln gene polymorphism and susceptibility to colorectal cancer:a meta-analysis. Tumor Biol. 2013;34:555–63.CrossRef Zeng FR, Ling Y, Yang J, Tian XC, Yang X, Luo RC. X-ray repair cross-complementing group 1 Arg399Gln gene polymorphism and susceptibility to colorectal cancer:a meta-analysis. Tumor Biol. 2013;34:555–63.CrossRef
26.
Zurück zum Zitat Fujimori Y, Inokuchi M, Takagi Y, Kato K, Kojima K, Sugihara K. Prognostic value of RKIP and p-ERK in gastric cancer. J Exp Clin Cancer Res. 2012;31:30.PubMedCentralPubMedCrossRef Fujimori Y, Inokuchi M, Takagi Y, Kato K, Kojima K, Sugihara K. Prognostic value of RKIP and p-ERK in gastric cancer. J Exp Clin Cancer Res. 2012;31:30.PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Mao W, Chen J, Peng TL, Yin XF, Chen LZ, Chen MH. Downregulation of gastrokine-1 in gastric cancer tissues and restoration of its expression induced gastric cancer cells to apoptosis. J Exp Clin Cancer Res. 2012;31:49.PubMedCentralPubMedCrossRef Mao W, Chen J, Peng TL, Yin XF, Chen LZ, Chen MH. Downregulation of gastrokine-1 in gastric cancer tissues and restoration of its expression induced gastric cancer cells to apoptosis. J Exp Clin Cancer Res. 2012;31:49.PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Malhotra P, Anwar M, Nanda N, Kochhar R, Wig JD, Vaiphei K, et al. Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians. Tumor Biol. 2013;34:1901–11.CrossRef Malhotra P, Anwar M, Nanda N, Kochhar R, Wig JD, Vaiphei K, et al. Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians. Tumor Biol. 2013;34:1901–11.CrossRef
29.
Zurück zum Zitat Wikberg ML, Edin S, Lundberg IV, Van Guelpen B, Dahlin AM, Rutegård J, et al. High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumor Biol. 2013;34:1013–20.CrossRef Wikberg ML, Edin S, Lundberg IV, Van Guelpen B, Dahlin AM, Rutegård J, et al. High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumor Biol. 2013;34:1013–20.CrossRef
30.
Zurück zum Zitat Findeisen P, Costina V, Yepes D, Hofheinz R, Neumaier M. Functional protease profiling with reporter peptides in serum specimens of colorectal cancer patients: demonstration of its routine diagnostic applicability. J Exp Clin Cancer Res. 2012;31:56.PubMedCentralPubMedCrossRef Findeisen P, Costina V, Yepes D, Hofheinz R, Neumaier M. Functional protease profiling with reporter peptides in serum specimens of colorectal cancer patients: demonstration of its routine diagnostic applicability. J Exp Clin Cancer Res. 2012;31:56.PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Song M, Zang W, Zhang B, Cao J, Yang G. GCS overexpression is associated with multidrug resistance of human HCT-8 colon cancer cells. J Exp Clin Cancer Res. 2012;31:23.PubMedCentralPubMedCrossRef Song M, Zang W, Zhang B, Cao J, Yang G. GCS overexpression is associated with multidrug resistance of human HCT-8 colon cancer cells. J Exp Clin Cancer Res. 2012;31:23.PubMedCentralPubMedCrossRef
Metadaten
Titel
Lack of association between interleukin-4 −524C>T polymorphism and colorectal cancer susceptibility
verfasst von
Huanlei Wu
Jia Hu
Bo Liu
Yu Tao
Xiao Zhou
Xianglin Yuan
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1484-6

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.